BPC-157

Summary

BPC-157 ("Body Protection Compound 157") is a lab-made peptide of 15 amino acids, based on a fragment of a protein found in human gastric juice. It is promoted online and on podcasts as a near-universal healing aid — for tendons, ligaments, muscle, joints, and the gut. The honest state of the evidence is that almost everything we know comes from rat and cell studies: a 2025 systematic review found roughly 35 preclinical studies but only about one clinical study, and zero randomized controlled trials in humans. It is not approved for human use anywhere and is banned in sport.

What people use it for

In the biohacker and athlete communities, BPC-157 is discussed mainly as an injury-recovery and "tissue repair" compound — for tendon and ligament strains, muscle tears, post-surgical recovery, and joint pain — and as a "gut-healing" agent for issues like leaky gut, ulcers, and IBD. It is often injected (subcutaneously near an injury) or taken orally. These are the claims the evidence sections below test; describing them here is not an endorsement.

Human evidence

Published human data on BPC-157 is very limited and low quality. A 2025 narrative review identified only three published human studies, all from the same physician/group (Edwin Lee, Institute for Hormonal Balance in Orlando), and a 2025 systematic review of orthopaedic use likewise found essentially one clinical study against dozens of animal studies.

The most cited human report is a 2021 retrospective chart review by Lee and Padgett: a single-clinic review of 16 patients given intra-articular knee injections of BPC-157 (alone or combined with TB-500), of whom 14 of 16 (about 88%) reported pain relief. The authors and later reviewers note major limitations — small sample, no control group, mixed underlying diagnoses, and retrospective self-reported outcomes — so it cannot establish that BPC-157 caused the improvement. The other two reports are small pilots (an interstitial-cystitis pilot of 12 patients, and an intravenous safety pilot in just 2 healthy adults). No randomized controlled trial has tested BPC-157 for any indication in humans.

A frequently repeated claim that BPC-157 was "shown safe in clinical trials for inflammatory bowel disease" turns out to have a real but underwhelming basis. According to 2026 reporting by Undark (co-published with STAT News), the Croatian pharmaceutical company PLIVA — which licensed the peptide in 1993 — ran two early-stage human trials in the early 2000s testing BPC-157 (as PL-14736) for ulcerative colitis. The full results were never published; a short 2005 write-up reported that the second trial found a positive effect that did not reach statistical significance. The project later passed to GlaxoSmithKline through acquisitions and was dropped. A separate trial begun around 2015 in Tijuana — sponsored by a company that lists the lead researcher as a partial owner — is listed as canceled in the U.S. government registry; the research team says it found the peptide "safe and well-tolerated" but has not published the data. So the honest version of the "it was in human trials" claim is: yes, there were early-stage trials two decades ago, they were not clearly positive, and they were never fully published.

There is also an unresolved scientific dispute about what BPC-157 even is. It is widely marketed as a "natural" substance the human body produces. But in the Undark reporting, peptide chemists — including Anna Mapp, president of the American Peptide Society, and Patricia Brubaker of the University of Toronto — noted that BPC-157's amino-acid sequence has not been found in the human genome or gut microbiome, that no dedicated receptor for it has been identified (most peptide drugs act through receptors), and that the parent protein's full sequence was never published, which makes the original discovery impossible to independently reproduce. Some researchers suspect the original team may have misread an amino-acid sequence decades ago with the cruder analytical tools of the time. The lead researcher disputes this and points to his lab's imaging work, though at least one outside scientist said she did not find that evidence convincing. The practical upshot for readers: the common "it's just something your body makes" framing is contested by mainstream peptide scientists.

One reason to read the BPC-157 literature cautiously is its concentration. A 2026 investigative report by Undark found that the large majority of the roughly 200 BPC-157 studies indexed on PubMed list the same two Croatian researchers (Predrag Sikiric and Sven Seiwerth) as principal authors, and that financial conflicts of interest — including BPC-157 patents and ownership stakes in companies developing the peptide — were not disclosed on the team's published papers. Independent reviewers (including teams in the U.S., U.K., and Poland) have generally called the compound promising but cautioned that the evidence is dominated by a single group and that the risk of confirmation bias, absent independent replication, is real. None of this proves the findings are wrong, but it is a strong reason not to treat the volume of positive studies as if it were independent corroboration.

Newer human research is being attempted. A hamstring-strain trial was registered in 2026 (NCT07437547) but is not yet completed, and a Johns Hopkins pain physician told Undark he is seeking government (ARPA-H) funding to run clinical trials of BPC-157 and other peptides for chronic pain. As of this writing, none of these has produced published results.

Animal / preclinical evidence

This is where nearly all of the evidence sits, and it is consistently positive in rodents. In a foundational 2003 study, rats with a fully transected Achilles tendon healed faster on BPC-157 than controls across biomechanical (load-to-failure, stiffness), functional, and histological measures. Cell and mechanism studies suggest plausible pathways: BPC-157 promotes angiogenesis (new blood-vessel growth, relevant because tendons heal slowly partly due to poor blood supply), stimulates fibroblast/tendocyte migration and growth, and upregulates the growth-hormone receptor in tendon fibroblasts. Reviewers summarize comparable preclinical effects across muscle, ligament, bone, and gastrointestinal-injury models.

The important caveat is translational: these are rat and in-vitro findings at controlled doses, and reviewers repeatedly stress that rodent physiology does not reliably predict human efficacy or safety. Preclinical promise is not the same as a working human therapy.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

In forums, podcasts, and athlete circles, BPC-157 is described as fast-acting for nagging tendon, joint, and soft-tissue injuries, often based on personal n-of-1 experience and social-media promotion rather than testing. BPC-157 and TB-500 are frequently paired and marketed together as a so-called "Wolverine stack" for accelerated whole-body healing. There is no controlled human study of that combination; the only place the two appear together in published human data is the small retrospective knee-pain chart review above, which cannot isolate either peptide's effect, let alone the combination's. Treat the "stack" as an unverified community protocol, not an evidence-based one.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

Published animal studies most often used BPC-157 at 10 µg/kg and 10 ng/kg (and sometimes 10 pg/kg) given intraperitoneally in rats — for example in the 2003 transected-Achilles-tendon study. These are rodent doses and do not translate to a human dose. Published human dosing is minimal and not standardized: the 2021 chart review used intra-articular injections in a clinic setting, and a 2025 pilot used escalating intravenous doses in two volunteers. In public discussion, podcaster Andrew Huberman has described a commonly cited community protocol of roughly 300–500 mcg subcutaneously a few times per week, cycled on and off rather than taken continuously — but he frames this as an informal, animal-data-extrapolated protocol with no official guidelines, not a validated dose. Because there are no controlled human trials, there is no established or validated human dose.

Safety & side effects

The human safety profile is not well established — that is the honest summary. The small human reports above described no notable adverse effects, but they involved very few patients and were not designed to detect harm. The FDA states that for BPC-157 it "lacks sufficient information to know whether the drug would cause harm when administered to humans," and flags potential immunogenicity (immune reactions) and peptide-impurity/characterization concerns. Because BPC-157 promotes angiogenesis, reviewers have raised a theoretical concern that it could also support tumor blood-vessel growth; this is a mechanistic concern, not a demonstrated human effect, and has not been studied in people. A separate real-world risk is product quality: gray-market "research only" vials are unregulated and may be underdosed, contaminated, or not contain what the label claims.

Regulatory / legal status

BPC-157 is not FDA-approved for any use and is not a lawful dietary ingredient. Its compounding status is in active flux as of mid-2026, and it's easy to be misled by it. Here is the careful version: BPC-157 had been placed in the FDA's compounding "Category 2" (substances that may present significant safety risks). In April 2026 it was removed from Category 2 — but only because the nominations to add it to the approved 503A bulks list were withdrawn, a procedural change that, as legal analysts note, does not on its own authorize pharmacies to compound it. The FDA's stated safety concerns (potential immunogenicity, peptide-impurity and characterization issues, and limited human data) remain on record. An FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026 will formally consider whether BPC-157 (and several other peptides, including TB-500) should be added to the 503A list; only a favorable recommendation followed by a final FDA rule would actually make legal compounding possible. Until then, BPC-157 reaching consumers comes through unregulated research-chemical channels, not licensed pharmacies.

This has become politically charged. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly supported expanding access to unapproved peptides like BPC-157, arguing that it is not the FDA's role to stop adults from trying experimental medicine and that letting people obtain these substances from licensed pharmacies would be safer than the existing gray market. He framed the April 2026 action as beginning to restore regulated access and shift demand away from unregulated sources. Reporting also noted a tension in his public statements: in one April 2026 post he said the advisory committee would weigh the "full clinical, pharmacological, and safety evidence," while around the same time he suggested these peptides are more like supplements and might not need to go through clinical trials. We note this as documented policy context, not as an endorsement of any position; readers should understand that a substance's regulatory status can be shaped by politics as well as by data, and that "may soon be available from a pharmacy" is not the same as "proven safe and effective."

In sport, the World Anti-Doping Agency added BPC-157 to its Prohibited List (class S0, non-approved substances) effective 2022, and it appears on the U.S. Department of Defense prohibited dietary-supplement-ingredient list. Status varies by country and can change; this is not legal advice.

Podcast / media mentions

BPC-157 is a staple of longevity and fitness podcasts and influencer content, where it is often presented as a proven, fast healing aid and bundled with TB-500 as a "Wolverine stack." That framing runs well ahead of the evidence: the strong data is preclinical (rats and cells), the human data is three tiny uncontrolled studies, and no RCT exists.

A useful, more careful example is the Huberman Lab podcast. Andrew Huberman has discussed BPC-157 at length and disclosed personal subcutaneous use, saying he heals "noticeably faster" on it — but he pairs that with several cautions that square reasonably well with the evidence above. He states plainly that there is essentially zero human data and "tons of animal data"; he advises against continuous use and against oral formulations (citing contamination of gray-market product); and his central safety warning is the angiogenesis concern — because BPC-157 promotes new blood-vessel growth via VEGF, he cautions against use by anyone with, or concerned about, cancer, since tumors also depend on angiogenesis. His own disclosure that he sources via a compounding pharmacy with a prescription is worth noting against the current regulatory reality: as of 2026, compounding BPC-157 is not permitted (see Regulatory status), so that route is narrower than it may sound.

It's worth flagging that Huberman's cancer caution is itself contested. Some peptide-prescribing physicians have argued the analogy is too simple — that BPC-157's angiogenesis appears to be triggered by injury signals rather than acting indiscriminately, so the jump to "promotes tumors" may overstate the risk. That counter-argument is plausible mechanistically but unproven in humans, and it comes from clinicians who prescribe peptides commercially, so it carries its own potential bias. The honest read is that the tumor-growth risk is a theoretical, unresolved concern in both directions — not a settled fact and not a debunked myth. As always, the critique here is of the claims and the certainty attached to them, not of the people making them.

Beyond fitness podcasts, BPC-157 has become a cause within the "Make America Healthy Again" (MAHA) movement, which frames it as a promising therapy spurned by big pharma and gatekept by an overly paternalistic FDA. On a December 2025 episode of his podcast, wellness entrepreneur Gary Brecka listed roughly half a dozen diseases he believes BPC-157 can treat and described "astounding results" to a guest who was then the FDA commissioner — claims that go far beyond what the published human evidence (essentially three tiny uncontrolled studies) can support. The political dimension is covered in the regulatory section above. For readers, the thing to hold onto is that the loudest promotion of BPC-157 is now coming from people with strong commercial or ideological investments in its success, and that the volume and confidence of these claims do not reflect a corresponding volume of human evidence.